MedTrace Logo

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

NCT05158491 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2022-01-05

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC)

Conditions

  • Small Cell Lung Cancer (SCLC)

Interventions

DRUG

JK-1201I

JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • JenKem Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xuan Zhao, Ph.D. · JenKem Technology Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05158491 on ClinicalTrials.gov